Budget-Impact-Analysis Of Iron Treatment Using Intravenous Ferric Carboxymaltose In Patients With Chronic Heart Failure And Iron Deficiency In Austria.

CONTACT: Sandra Ressl, MA IPF Institute for Pharmaeconomic Research Wolfengasse 4/7 1010 Vienna, Austria Tel +43-1-5132007-13 Fax +43-1-5132007-15 Email: [email protected] Web: www.ipf-ac.at Objectives Iron deficiency (ID), a non-cardiovascular comorbidity, is highly prevalent in chronic heart failure (CHF) patients and imposes a significant disease burden for CHF patients with enormous impact on their outcome and health care costs. CHF with ID is a major reason for hospitalization and represents important costs for the national health care budget in Austria. Yet, only a small percentage of CHF patients with ID are diagnosed. Based on IMS sales data (MAT4 2012 MAT4 2013, MAT 4 2014) around 30% of patients with iron deficiency or iron deficiency anemia obtain iron therapy. 80% receive oral iron therapy and only 20% iv iron therapy.